+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Serine/Threonine Protein Kinase A Raf - Pipeline Review, H1 2020

  • ID: 5128971
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 34 pages
  • Global Markets Direct

FEATURED COMPANIES

  • DOT Therapeutics-1 Inc
  • Jazz Pharmaceuticals Plc
  • Novartis AG
  • Redx Pharma Plc
  • Samjin Pharm Co Ltd
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Serine/Threonine Protein Kinase A Raf - Pipeline Review, H1 2020

Summary

Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase A Raf - Pipeline Review, H1 2020, outlays comprehensive information on the Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Serine/threonine-protein kinase A-Raf is an enzyme that in humans is encoded by the ARAF gene. It is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It regulates the TOR signaling cascade. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Musculoskeletal Disorders which include indications Colorectal Cancer, Fibrosis, Low-Grade Glioma, Melanoma, Metastatic Melanoma and Non-Small Cell Lung Cancer.

Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • DOT Therapeutics-1 Inc
  • Jazz Pharmaceuticals Plc
  • Novartis AG
  • Redx Pharma Plc
  • Samjin Pharm Co Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Overview
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • DOT Therapeutics-1 Inc
  • Jazz Pharmaceuticals Plc
  • Novartis AG
  • Redx Pharma Plc
  • Samjin Pharm Co Ltd
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Drug Profiles
  • INU-152 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LXH-254 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REDX-05358 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SJP-601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Pan-RAF Kinase Musculoskeletal Disorders and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-580 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Dormant Products
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Discontinued Products
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors
  • Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
  • Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by DOT Therapeutics-1 Inc, H1 2020
  • Pipeline by Jazz Pharmaceuticals Plc, H1 2020
  • Pipeline by Novartis AG, H1 2020
  • Pipeline by Redx Pharma Plc, H1 2020
  • Pipeline by Samjin Pharm Co Ltd, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
Note: Product cover images may vary from those shown
  • DOT Therapeutics-1 Inc
  • Jazz Pharmaceuticals Plc
  • Novartis AG
  • Redx Pharma Plc
  • Samjin Pharm Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll